生物分子模拟论坛

 找回密码
 我想注册

QQ登录

只需一步,快速开始

扫一扫,访问微社区

查看: 1937|回复: 5

[研发新闻] 全球新公布的药物专利(2014.9.6-2014.9.12)

[复制链接]
发表于 2014-9-12 20:21:15 | 显示全部楼层 |阅读模式

马上注册,结交更多好友,下载更多分子模拟资源。

您需要 登录 才可以下载或查看,没有帐号?我想注册

x

       著名经济学家曼斯菲尔德曾研究分析得出结论,如果没有专利保护,60%的新药就不会被发明出来,这充分说明了专利保护对药物研发的重要意义。在新药的4中知识产权保护中,也只有专利保护是国家以法律形式确定的保护,且具有独占性、力度强、范围广、保护时间长等特点,是最全面、最高级别的保护。(2014.9.6-2014.9.12)内,在全球新公布的药物专利,呈现给各位。


1. WO 2014121883

标题: Substituted acetylene derivatives and their use as positive allosteric modulators of mGluR4

申请人: 默克

优先权日期及相关专利公开号: 2013 US 762000

相关候选药物类型: 小分子药物

相关候选药物化学结构:


                               
登录/注册后可看大图


适应症: 精神疾病、2型糖尿病、胃食管反流病、肠炎、黄斑变性、药物滥用和依赖

     专利摘要: The present invention relates to novel acetylene derivatives as positive allosteric modulators for modulating metabotropic glutamate receptor subtype 4 (mGluR4) and/or altering glutamate level or glutamatergic signalling.

备注:

mGluR4受体正向变构调控剂可以治疗精神疾病(如注意力缺陷、多动症、焦虑和情绪异常)、神经退行性疾病(如帕金森症)、2型糖尿病、胃食管反流病、肠炎、黄斑变性、药物滥用和依赖。本发明的的化合物对mGluR4受体的EC50 1 mcM。


2. WO 2014117920

标题: Spiro-quinazolinone derivatives useful for the treatment of neurological diseases and conditions

申请人: 默克

优先权日期及相关专利公开号: 2013 US 760367

相关候选药物类型: 小分子药物

相关候选药物化学结构:


                               
登录/注册后可看大图

适应症: 精神疾病、2型糖尿病、胃食管反流病、肠炎、黄斑变性、药物滥用和依赖

专利摘要: The present invention relates to novel spiro-quinazolinone derivatives as positive allosteric modulators for modulating metabotropic glutamate receptor subtype 4 (mGluR4) and/or altering glutamate level or glutamatergic signalling

备注: mGluR4受体正向变构调控剂可以治疗精神疾病(如注意力缺陷、多动症、焦虑和情绪异常)、神经退行性疾病(如帕金森症)、2型糖尿病、胃食管反流病、肠炎、黄斑变性、药物滥用和依赖。本发明的的化合物对mGluR4受体的EC50 1 mcM。


3. WO 2014120346

标题: Factor IXa inhibitors

申请人: 默克

优先权日期及相关专利公开号: 2012 US 739266

相关候选药物类型: 小分子药物

相关候选药物化学结构:


                               
登录/注册后可看大图

适应症: 血栓

专利摘要: The present invention provides a compound of Formula (I) (structurally represented) wherein R1 is H or C1-6 alkyl, R2 is H or C1-6 alkyl or CH20H, R3 is H or C1-6 alkyl, and R4 is H or C1-6 alkyl, provided that when R1, R2, and R3 are H, R4 is C1-6 alkyl, and when R1, R2, and R4 are H, then R3 is C1-6 alkyl, and when R1, R3, and R4 are H, R2 is C1-6 alkyl or-CH20H, and when R2, R3, and R4 are H, then R1 is C 1-6 alkyl; A is 1 ) a 9-10 membered bicyclic heterocycle having 1-3 heteroatoms independently selected from N, S and 0, which 9-10 membered bicyclic heterocycle is unsubstituted or substituted with R5 and unsubstituted or substituted with R6 and unsubstituted or substituted with NH2, or 2) a 6-9 membered monocyclic or bicyclic carbocyclic ring system unsubstituted or substituted with R5, unsubstituted or substituted with R6, and unsubstituted or substituted with -CH2NH2; and B is 1) a 5- or 6-membered monocyclic heterocycle having 1 or 2 heteroatoms independently selected from N, S or 0, which is unsubstituted or substituted on a carbon or nitrogen atom with R7, unsubstituted or substituted on a carbon or nitrogen atom with R8, and unsubstituted or substituted on a carbon or nitrogen atom with R9, or 2) an 8- or 9-membered fused bicyclic heterocycle having 1, 2 or 3 nitrogen atoms which is unsubstituted or substituted on a carbon or nitrogen atom with R7, and unsubstituted or substituted on a carbon or nitrogen atom with R8; and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses.

备注: 凝血因子IXa抑制剂可以治疗血栓。本发明的化合物可以抑制凝血因子Ixa的活性,其IC50为1.345 nM.。


4. WO 2014121062

标题: Selective HDAC3 inhibitors

申请人: Acetylon Pharmaceuticals, Inc.

优先权日期及相关专利公开号: 2014 US 923023

相关候选药物类型: 小分子药物

相关候选药物化学结构:


                               
登录/注册后可看大图

适应症: 癌症、2型糖尿病、神经退行性疾病、镰状细胞贫血、地中海贫血症

专利摘要: Provided herein are HDAC3 inhibitors, as well as methods of treatment comprising administering these compounds to a subject in need thereof.

备注: HDAC3抑制剂可以治疗癌症、2型糖尿病、神经退行性疾病、镰状细胞贫血、地中海贫血症。本发明的化合物可以抑制HDAC3 (IC50 = 30 nM),且对HDAC1 和HDAC2 具有选择性(IC50 分别等于462 和228 nM)。


5. WO 2014117947

标题: 4-Amino substituted condensed pyrimidine compounds as PDE4 inhibitors

申请人: Gruenenthal GmbH

优先权日期及相关专利公开号: 2013 EP 565

相关候选药物类型: 小分子药物

相关候选药物化学结构:


                               
登录/注册后可看大图

适应症: 哮喘、过敏性鼻炎、类风湿性关节炎、银屑病、肠炎、慢性阻塞性肺病、癌症

专利摘要: The invention relates to novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.

备注: PDE4B抑制剂可以治疗哮喘、过敏性鼻炎、类风湿性关节炎、银屑病、肠炎、慢性阻塞性肺病、癌症、痛风、葡萄膜炎、阿尔兹海默等多种疾病。本发明的化合物可以抑制PDE4B1活性(IC50 = 0.07 mcM) ,且对PDE4D2具有50倍的选择性。


6. WO 2014117948

标题: Novel substituted condensed pyrimidine compounds

申请人: Gruenenthal GmbH

优先权日期及相关专利公开号: 2013 EP 550

相关候选药物类型: 小分子药物

相关候选药物化学结构:


                               
登录/注册后可看大图

适应症: 哮喘、过敏性鼻炎、类风湿性关节炎、银屑病、肠炎、慢性阻塞性肺病、癌症

专利摘要: The invention relates to novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.

备注: PDE4B抑制剂可以治疗哮喘、过敏性鼻炎、类风湿性关节炎、银屑病、肠炎、慢性阻塞性肺病、癌症、痛风、葡萄膜炎、阿尔兹海默等多种疾病。本发明的化合物可以抑制PDE4B1活性IC500.1 mcM 。


7. WO 2014117676

标题: N- and S-containing heterocyclic compound having DHODH inhibiting activity and preparation and use thereof

申请人: East China University of Science and Technology (ECUST)

优先权日期及相关专利公开号: 2013 CN 10039793

相关候选药物类型: 小分子药物

相关候选药物化学结构:


                               
登录/注册后可看大图

适应症: 癌症、自身免疫类疾病、类风湿性关节炎、红斑狼疮

专利摘要: The present invention relates to an N- and S-containing heterocyclic compound having DHODH inhibiting activity and a preparation and use thereof. In particular, disclosed in the present invention are a compound of general formula (I), or an optical isomer, a cis-trans isomer or a pharmaceutically acceptable salt thereof, and the preparation method thereof. This compound has excellent dihydroorotate dehydrogenase inhibiting activity, thereby being used for treating or preventing diseases such as inflammatory diseases, for example, autoimmune diseases, rheumatoid arthritis and lupus erythematosus, destructive bone disorders, malignant nephrosclerosis disease, vascular diseases and infectious diseases.

备注: DHODH抑制剂可以治疗癌症、自身免疫类疾病、类风湿性关节炎、红斑狼疮等疾病。本发明的化合物可以抑制DHODH 的活性(IC50 = 0.12 mcM)。


8. WO 2014117718

标题: Substituted 2-aminopyridine protein kinase inhibitor

申请人: Centaurus BioPharma Co., Ltd.

优先权日期及相关专利公开号: 2013 CN 10051822

相关候选药物类型: 小分子药物

相关候选药物化学结构:


                               
登录/注册后可看大图

适应症: 癌症

专利摘要: Disclosed are a 2-aminopyridine derivative having protein kinase inhibition activity, preparation method and pharmaceutical composition thereof. Also disclosed are uses of the compound and the pharmaceutical composition thereof in the preparation of drugs for treating and/or preventing protein kinase-related diseases.

备注: ALK抑制剂可以治疗癌症。本发明的化合物可以抑制ALK活性(IC50=1.96 nM),对ALK突变的L1196M和G1269S的IC50分别为35.1和61.3nM。


9. WO 2014118229

标题: Substituted thienopyrimidines and pharmaceutical use thereof

申请人: 拜耳

优先权日期及相关专利公开号: 2013 EP 153619

相关候选药物类型: 小分子药物

相关候选药物化学结构:


                               
登录/注册后可看大图

适应症: 癌症

专利摘要: The present invention relates to substituted thienopyrimidine compounds of general formula(I)as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

备注: MNK1抑制剂可以治疗癌症。本发明的化合物可以抑制MNK1 (IC50 = 1.4 nM)。


10. WO 2014118135

标题: Amidoimidazopyridazines as MKNK-1 kinase inhibitors

申请人: 拜耳

优先权日期及相关专利公开号: 2013 EP 153340

相关候选药物类型: 小分子药物

相关候选药物化学结构:


                               
登录/注册后可看大图

适应症: 癌症

专利摘要: The present invention relates to amido-substituted imidazopyridazine compounds of general formula (I) : in which A, R1, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper- proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

备注: MNK1抑制剂可以治疗癌症。本发明的化合物可以抑制MNK1 (IC50 = 3 ~ 11 nM 。


11. WO 2014119947

标题: Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as CETP inhibitors

申请人: Chong Kun Dang Holdings Corp.

优先权日期及相关专利公开号: 2013 KR 11206

相关候选药物类型: 小分子药物

相关候选药物化学结构:


                               
登录/注册后可看大图

适应症: 血脂异常、心绞痛、心肌梗塞、动脉硬化

专利摘要: The present invention provides biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds, isomers thereof, or pharmaceutically acceptable salts. The compounds of the invention show a CETP inhibitory effect that increases HDL-cholesterol levels and reduces LDL-cholesterol levels. Pharmaceutical compositions comprising the compounds are useful for the prevention or treatment of dyslipidemia or dyslipidemia-related diseases.

备注: CETP抑制剂可以增加高密度脂蛋白水平,且降低低密度脂蛋白水平,因此可以治疗血脂异常及血脂异常相关疾病,如心绞痛、心肌梗塞、动脉硬化。本发明的化合物可以抑制[3H]-cholesteryl oleate至LDL(IC50=5.4 nM)。


12. WO 2014120764

标题: S1P modulating agents

申请人: 百健艾迪

优先权日期及相关专利公开号: 2013 US 865846

相关候选药物类型: 小分子药物

相关候选药物化学结构:


                               
登录/注册后可看大图

适应症: 多发性硬化症、疼痛、类风湿性关节炎

专利摘要: Compounds of formula (I) can modulate the activity of one or more S 1P receptors. Sphingosine 1-phosphate (S IP) is a lysophospholipid mediator that evokes a variety of cellular responses by stimulation of five members of the endothelial cell differentiation gene (EDG) receptor family, namely S1P1, S1P2, S1P3, S1P4, and S1P5 (formerly EDG1, EDG5, EDG3, EDG6 and EDG8). The EDG receptors are G-protein coupled receptors (GPCRs) and on stimulation propagate second messenger signals via activation of heterotrimeric G-protein alpha (Ga.) subunits and beta-gamma (G()y) dimers.

备注: S1P5受体调控及可以治疗多发性硬化症、疼痛、类风湿性关节炎和脱髓鞘疾病、神经退行性疾病、认知障碍本发明的化合物可以拮抗S1P5受体活性(EC50 100 nM)。


发表于 2014-9-13 18:17:05 | 显示全部楼层
都是好东西
发表于 2014-9-14 16:41:27 | 显示全部楼层
DHODH那个是华理的呀,不错。
发表于 2014-9-15 09:49:28 | 显示全部楼层
请问专利里有指出结构中哪部分是受保护的吗?怎么样算突破专利啊?
 楼主| 发表于 2014-9-15 12:52:20 | 显示全部楼层
Qi乐无穷 发表于 2014-9-15 09:49
请问专利里有指出结构中哪部分是受保护的吗?怎么样算突破专利啊?

专利里是有claim的,对其结构有限制,不在限制之内的就算的突破。
您需要登录后才可以回帖 登录 | 我想注册

本版积分规则

QQ|分迪科技|小黑屋|手机版|Archiver|生物分子模拟论坛 ( 蜀ICP备14009200号-3 )

GMT+8, 2020-8-15 01:22 , Processed in 0.065452 second(s), 26 queries .

Powered by Discuz! X3.4

© 2001-2017 Comsenz Inc.

快速回复 返回顶部 返回列表